ANI Pharmaceuticals (NASDAQ:ANIP) updated its FY19 earnings guidance on Wednesday. The company provided EPS guidance of $5.06-5.23 for the period, compared to the Thomson Reuters consensus EPS estimate of $5.73. The company issued revenue guidance of $209-212 million, compared to the consensus revenue estimate of $222.57 million.
A number of research firms have commented on ANIP. Raymond James lowered their price objective on ANI Pharmaceuticals from $82.00 to $75.00 and set an outperform rating on the stock in a research note on Thursday. BidaskClub upgraded ANI Pharmaceuticals from a hold rating to a buy rating in a research note on Tuesday, October 22nd. Zacks Investment Research upgraded ANI Pharmaceuticals from a sell rating to a hold rating in a research note on Friday, October 4th. Guggenheim assumed coverage on ANI Pharmaceuticals in a research note on Thursday, September 12th. They issued a buy rating and a $76.00 price target on the stock. Finally, ValuEngine lowered ANI Pharmaceuticals from a sell rating to a strong sell rating in a research note on Thursday. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the stock. ANI Pharmaceuticals has a consensus rating of Buy and a consensus target price of $85.00.
Shares of ANIP traded down $1.57 during midday trading on Friday, hitting $59.86. The company’s stock had a trading volume of 9,125 shares, compared to its average volume of 169,781. ANI Pharmaceuticals has a one year low of $36.92 and a one year high of $86.96. The company’s fifty day simple moving average is $73.94 and its two-hundred day simple moving average is $73.64. The company has a quick ratio of 0.74, a current ratio of 1.01 and a debt-to-equity ratio of 0.32. The stock has a market capitalization of $954.49 million, a price-to-earnings ratio of 13.08 and a beta of 2.20.
ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings results on Wednesday, November 6th. The specialty pharmaceutical company reported $1.23 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $1.43 by ($0.20). ANI Pharmaceuticals had a net margin of 8.14% and a return on equity of 29.53%. The business had revenue of $51.30 million during the quarter, compared to the consensus estimate of $56.10 million. During the same quarter in the previous year, the business posted $1.29 EPS. The company’s revenue for the quarter was up 1.2% on a year-over-year basis. On average, research analysts predict that ANI Pharmaceuticals will post 5.29 earnings per share for the current year.
In related news, major shareholder Meridian Venture Partners Ii L sold 61,697 shares of the firm’s stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $71.64, for a total transaction of $4,419,973.08. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In the last three months, insiders have sold 78,591 shares of company stock worth $5,582,839. 24.70% of the stock is currently owned by company insiders.
About ANI Pharmaceuticals
ANI Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncolytics (anti-cancers), hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract manufacturing for other pharmaceutical companies.
Featured Story: What is the return on assets formula?
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.